{"id":822434,"date":"2025-03-06T07:12:36","date_gmt":"2025-03-06T12:12:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/"},"modified":"2025-03-06T07:12:36","modified_gmt":"2025-03-06T12:12:36","slug":"cartesian-therapeutics-announces-new-employment-inducement-grant","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/","title":{"rendered":"Cartesian Therapeutics Announces New Employment Inducement Grant"},"content":{"rendered":"
\n

FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company\u2019s common stock with an exercise price of $17.50, the closing trading price of the Company\u2019s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company\u2019s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company\u2019s board of directors. The option vests as to 25% on March 3, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on March 3, 2029. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee\u2019s entry into employment with the Company.<\/p>\n

\n About Cartesian Therapeutics<\/strong>\n <\/p>\n

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company\u2019s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company\u2019s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com<\/a> or follow the Company on LinkedIn<\/a> or X<\/a>, formerly known as Twitter.<\/p>\n

\n Contact Information:<\/strong>
\n
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com<\/a><\/p>\n

Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company\u2019s common stock with an exercise price of $17.50, the closing trading price of the Company\u2019s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company\u2019s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company\u2019s board of directors. The option vests as to 25% on … <\/p>\n

Continue reading “Cartesian Therapeutics Announces New Employment Inducement Grant”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-822434","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCartesian Therapeutics Announces New Employment Inducement Grant - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cartesian Therapeutics Announces New Employment Inducement Grant - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company\u2019s common stock with an exercise price of $17.50, the closing trading price of the Company\u2019s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company\u2019s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company\u2019s board of directors. The option vests as to 25% on … Continue reading "Cartesian Therapeutics Announces New Employment Inducement Grant"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-06T12:12:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTkzMCM2NzkyOTc0IzIwNTAxMjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cartesian Therapeutics Announces New Employment Inducement Grant\",\"datePublished\":\"2025-03-06T12:12:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/\"},\"wordCount\":287,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTkzMCM2NzkyOTc0IzIwNTAxMjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/\",\"name\":\"Cartesian Therapeutics Announces New Employment Inducement Grant - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTkzMCM2NzkyOTc0IzIwNTAxMjk=\",\"datePublished\":\"2025-03-06T12:12:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTkzMCM2NzkyOTc0IzIwNTAxMjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTkzMCM2NzkyOTc0IzIwNTAxMjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-announces-new-employment-inducement-grant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cartesian Therapeutics Announces New Employment Inducement Grant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cartesian Therapeutics Announces New Employment Inducement Grant - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/","og_locale":"en_US","og_type":"article","og_title":"Cartesian Therapeutics Announces New Employment Inducement Grant - Market Newsdesk","og_description":"FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company\u2019s common stock with an exercise price of $17.50, the closing trading price of the Company\u2019s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company\u2019s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company\u2019s board of directors. The option vests as to 25% on … Continue reading \"Cartesian Therapeutics Announces New Employment Inducement Grant\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-06T12:12:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTkzMCM2NzkyOTc0IzIwNTAxMjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cartesian Therapeutics Announces New Employment Inducement Grant","datePublished":"2025-03-06T12:12:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/"},"wordCount":287,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTkzMCM2NzkyOTc0IzIwNTAxMjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/","name":"Cartesian Therapeutics Announces New Employment Inducement Grant - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTkzMCM2NzkyOTc0IzIwNTAxMjk=","datePublished":"2025-03-06T12:12:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTkzMCM2NzkyOTc0IzIwNTAxMjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTkzMCM2NzkyOTc0IzIwNTAxMjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-announces-new-employment-inducement-grant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cartesian Therapeutics Announces New Employment Inducement Grant"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=822434"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822434\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=822434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=822434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=822434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}